Infectious complications are a major cause of morbidity and mortality in patients with primary or secondary immunodeficiency. Prevention of infectious diseases by vaccines is among the most effective healthcare measures mainly for these subjects. However immunocompromised people vary in their degree of immunosuppression and susceptibility to infection and, therefore, represent a heterogeneous population with regard to immunization. To date there is no well- established evidence for use of vaccines in immunodeficient patients, and indications are not clearly defined even in high-quality reviews and in most of the guidelines prepared to provide recommendations for the active vaccination of immunocompromised hosts. The aim of this document is to issue recommendations based on published literature and the collective experience of the Italian primary immunodeficiency centers, about how and when vaccines can be used in immunocompromised patients, in order to facilitate physician decisions and to ensure the best immune protection with the lowest risk to the health of the patient. (C) 2018 Elsevier Ltd. All rights reserved.

Martire, B., Azzari, C., Badolato, R., Canessa, C., Cirillo, E., Gallo, V., et al. (2018). Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET). VACCINE, 36(24), 3541-3554 [10.1016/j.vaccine.2018.01.061].

Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)

Moschese V.
2018-01-01

Abstract

Infectious complications are a major cause of morbidity and mortality in patients with primary or secondary immunodeficiency. Prevention of infectious diseases by vaccines is among the most effective healthcare measures mainly for these subjects. However immunocompromised people vary in their degree of immunosuppression and susceptibility to infection and, therefore, represent a heterogeneous population with regard to immunization. To date there is no well- established evidence for use of vaccines in immunodeficient patients, and indications are not clearly defined even in high-quality reviews and in most of the guidelines prepared to provide recommendations for the active vaccination of immunocompromised hosts. The aim of this document is to issue recommendations based on published literature and the collective experience of the Italian primary immunodeficiency centers, about how and when vaccines can be used in immunocompromised patients, in order to facilitate physician decisions and to ensure the best immune protection with the lowest risk to the health of the patient. (C) 2018 Elsevier Ltd. All rights reserved.
2018
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA
English
Con Impact Factor ISI
Primary immunodeficiency; Secondary immunodeficiency; Syndromic immunodeficiency; Vaccination; Adult; Bacterial Infections; Bacterial Vaccines; Child; Health Policy; Humans; Immunization Schedule; Immunologic Deficiency Syndromes; Italy; Process Assessment (Health Care); Vaccination; Vaccines, Inactivated; Viral Vaccines; Virus Diseases; Immunocompromised Host; Practice Guidelines as Topic
Martire, B., Azzari, C., Badolato, R., Canessa, C., Cirillo, E., Gallo, V., et al. (2018). Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET). VACCINE, 36(24), 3541-3554 [10.1016/j.vaccine.2018.01.061].
Martire, B; Azzari, C; Badolato, R; Canessa, C; Cirillo, E; Gallo, V; Graziani, S; Lorenzini, T; Milito, C; Panza, R; Moschese, V
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
vaccination in immunocomprimised host.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 444.58 kB
Formato Adobe PDF
444.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/217643
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 32
social impact